Healthy Male Subjects Clinical Trial
Official title:
A Randomized, Open-Label, 2-Arm, Parallel Group, Single Dose, Multi-Centre Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System
Verified date | October 2023 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, open-label, 2-arm, parallel-group, single-dose, multi-center study in healthy male subjects to investigate the comparability of the pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using the proprietary on-body delivery system or a handheld syringe with hypodermic needle.
Status | Completed |
Enrollment | 151 |
Est. completion date | October 3, 2023 |
Est. primary completion date | May 14, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Healthy male subjects age 18-45 years at time of signing Informed Consent Form - Ability to comply with the study protocol - Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, during the treatment period and for 7 months after the dose of PH FDC SC - A body mass index (BMI) between 18 and 32 kilograms per metre squared (kg/m2), inclusive - Intact normal skin without potentially obscuring tattoos, pigmentation, or lesions in the area for intended injection on the thighs - Baseline LVEF=55% measured by echocardiogram (ECHO) - No history of hypersensitivity or confirmed, clinically significant and clinically relevant allergic reactions, either spontaneously or following any drug administration - No history of any clinically significant and clinically relevant cardiac condition - No history of previous anticancer treatments including pertuzumab, trastuzumab, anthracyclines, or any cardiotoxic drugs - No apparent family history of clinically significant and clinically relevant hypersensitivity, allergy, and severe cardiac diseases - No contraindications from detailed medical and surgical history and physical examinations - No previous enrollment in this study protocol and no concurrent enrollment in any other study protocol Exclusion Criteria: - Positive urine test for drugs of abuse as per local standard (for alcohol abuse, positive breath test is also acceptable) - Positive test result for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) 1 or 2, showing: History of exposure to HBV, HCV, or HIV; or Active viral hepatitis infection (HBV or HCV) or HIV infection - Systolic blood pressure =140 millimetres of mercury (mmHg) or <90 mmHg, or diastolic blood pressure >90 mmHg or <50 mmHg - Use of prohibited medications including non-prescription medications, nutraceuticals, nutritional supplements or any herbal remedies taken within 10 days or 5 times the elimination half-life (whichever is longer) prior to randomization into the study - Concomitant subcutaneous, intravenous, or any parenteral drugs within 90 days prior to screening - Participation in an investigational drug or device study within 90 days or five times the elimination half-life (whichever is longer) prior to screening - Donation of blood over 500 millilitres (mL) within 3 months prior to enrollment - Known severe hypersensitivity to plaster, medical adhesive tapes, or bandages - Known allergy to murine proteins, hyaluronidase, bee, or vespid venom, or any other ingredient in the formulation of rHuPH20 (Hylenex® recombinant [hyaluronidase human injection]) or any other ingredients and excipients in the formulation of PH FDC SC - Clinically significant abnormalities in laboratory test results (including hepatic and renal panels, CBC, chemistry panel, and urinalysis) - Clinically relevant electrocardiogram abnormalities at screening or Day -1 - History of any cardiac condition - Lower extremity edema or pathology (e.g., cellulitis, lymphatic disorder or prior surgery, pre-existing pain syndrome, previous lymph node dissection etc.) that could interfere with any protocol-specified outcome assessment - Any history of clinically significant and clinically relevant allergies, oncologic, psychiatric, gastrointestinal, renal, hepatic, cardiovascular or pulmonary disease - Concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in this study - Any clinically relevant history of systemic disease (e.g., malignancy, diabetes mellitus, gastrointestinal, renal, hepatic, cardiovascular, rheumatological, or pulmonary disease) - History of breast cancer or treatment for breast cancer - Current chronic daily treatment (continuous for >3 months) with corticosteroids (dose =10 mg/day methylprednisolone), excluding inhaled corticosteroids - Receipt of intravenous antibiotics for infection within 7 days prior to enrollment into the study |
Country | Name | City | State |
---|---|---|---|
Australia | CMAX Pty Ltd | Adelaide | South Australia |
Australia | Q-Pharm Pty Ltd; Nucleus Network Brisbane Clinic | Herston | Queensland |
Australia | Linear Clinical Research Ltd | Nedlands | Western Australia |
New Zealand | New Zealand Clinical Research - Auckland | Auckland | |
New Zealand | New Zealand Clinical Research - Christchurch | Christchurch |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
Australia, New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area Under the Time-Concentration Curve from the Start of Dosing to 63 Days (AUC0-62) of Serum Pertuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Primary | Area Under the Time-Concentration Curve from the Start of Dosing to 63 Days (AUC0-62) of Serum Trastuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Primary | Maximum Serum Concentration (Cmax) of Pertuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Primary | Maximum Serum Concentration (Cmax) of Trastuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Observed Serum Concentration of Pertuzumab on Day 22 | Day 22 | ||
Secondary | Observed Serum Concentration of Trastuzumab on Day 22 | Day 22 | ||
Secondary | Observed Serum Concentration of Pertuzumab on Day 63 | Day 63 | ||
Secondary | Observed Serum Concentration of Trastuzumab on Day 63 | Day 63 | ||
Secondary | Area Under the Time-Concentration Curve from the Start of Dosing Extrapolated to Infinity (AUC0-8) of Serum Pertuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Area Under the Time-Concentration Curve from the Start of Dosing Extrapolated to Infinity (AUC0-8) of Serum Trastuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Observed Time to Maximum Serum Concentration (tmax) of Pertuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Observed Time to Maximum Serum Concentration (tmax) of Trastuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Terminal Elimination Half-Life (t1/2) of Pertuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Terminal Elimination Half-Life (t1/2) of Trastuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Apparent Drug Clearance (CL/F) of Pertuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Apparent Drug Clearance (CL/F) of Trastuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Apparent Volume of Distribution (Vd/F) of Pertuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Apparent Volume of Distribution (Vd/F) of Trastuzumab | Predose (0 hour) and 2, 6, and 12 hours postdose on Day 1, and postdose on Days 2, 3, 5, 7, 9, 11, 15, 22, 35, 49, and 63 | ||
Secondary | Summary of the Number of Participants with at Least One Adverse Event, with Severity Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0) | From informed consent until safety follow-up visit (up to 7 months) | ||
Secondary | Change from Baseline Left Ventricular Ejection Fraction (LVEF) Over Time | Baseline, once between Days 20 and 35, and once between Days 56 and 63 | ||
Secondary | Change from Baseline Respiratory Rate Over Time | Baseline, Days 1, 2, 7, 22, and 63 | ||
Secondary | Change from Baseline Pulse Rate Over Time | Baseline, Days 1, 2, 7, 22, and 63 | ||
Secondary | Change from Baseline Body Temperature Over Time | Baseline, Days 1 and 63 | ||
Secondary | Change from Baseline Systolic Blood Pressure Over Time | Baseline, Days 1, 2, 7, 22, and 63 | ||
Secondary | Change from Baseline Diastolic Blood Pressure Over Time | Baseline, Days 1, 2, 7, 22, and 63 | ||
Secondary | Change from Baseline Electrocardiogram PR Interval Over Time | Baseline, Days 1, 2, 7, 22, and 63 | ||
Secondary | Change from Baseline Electrocardiogram QRS Interval Over Time | Baseline, Days 1, 2, 7, 22, and 63 | ||
Secondary | Change from Baseline Electrocardiogram Uncorrected QT Interval Over Time | Baseline, Days 1, 2, 7, 22, and 63 | ||
Secondary | Number of Participants with Abnormal Clinical Laboratory Test Results as a Shift from Baseline to the Maximum Post-Baseline Severity Grade | From Baseline until Day 63 | ||
Secondary | Pain Score at the Injection Site, Assessed by the Participant Using the 100-millimetre (mm) Visual Analog Scale | Day 1: pre-dose, during drug injection, after drug injection while removing the device or syringe, and 2 hours after drug injection | ||
Secondary | Number of Participants with Skin Irritation and Sensitization Reactions at the Injection Site | Day 1 | ||
Secondary | Number of Participants by Their Ratings of the Comfort of Wearing the On-Body Delivery System Device, as Reported in the Device Monitoring Questionnaire | The ratings will be made on a three-point scale as "Good", "Acceptable", or "Poor". | Day 1 | |
Secondary | Number of Healthcare Professionals by Their Ratings of Performance and Ease of Use of the On-Body Delivery System Device, as Reported in the Device Monitoring Questionnaire | The ratings will be made on a three-point scale as "Good", "Acceptable", or "Poor". | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05621447 -
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
|
Phase 1 | |
Completed |
NCT02901366 -
Mass Balance Study of FYU-981
|
Phase 2 | |
Not yet recruiting |
NCT01928563 -
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine
|
Phase 1 | |
Completed |
NCT05559554 -
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
|
Phase 1 | |
Completed |
NCT04512872 -
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT06111196 -
Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03317652 -
Effect of Sodium Nitroprusside on Cerebral Blood Flow
|
N/A | |
Completed |
NCT04655872 -
Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02609711 -
Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects
|
Phase 1 | |
Withdrawn |
NCT02560363 -
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT01261260 -
Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05072028 -
Mass Balance and Biotransformation Study of [14C]DBPR108 in Human
|
Phase 1 | |
Completed |
NCT05446233 -
ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT04839744 -
A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT05792917 -
Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT03576651 -
A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT04825431 -
Mass Balance Study of [14C] TAS-205 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01819779 -
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
|
Phase 1 | |
Completed |
NCT05126784 -
AVT03 With Prolia in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT04850638 -
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
|
Phase 1 |